{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:12:19Z","timestamp":1790039539056,"version":"4.0.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,6]]},"DOI":"10.7759\/cureus.66304","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T17:26:53Z","timestamp":1722965213000},"source":"Crossref","is-referenced-by-count":8,"title":["Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review"],"prefix":"10.7759","author":[{"given":"Oluwaremilekun","family":"Tolu-Akinnawo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiwalade","family":"Awosanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chike","family":"Nzerue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Okafor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-024-01622-w","article-title":"The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy","volume":"47","author":"Kario K","year":"2024","unstructured":"Kario K, Okura A, Hoshide S, Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024, 47:1099-102. 10.1038\/s41440-024-01622-w","journal-title":"Hypertens Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19043","article-title":"Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015","volume":"317","author":"Forouzanfar MH","year":"2017","unstructured":"Forouzanfar MH, Liu P, Roth GA, et al.. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017, 317:165-82. 10.1001\/jama.2016.19043","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ash\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"71","author":"Whelton PK","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al.. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ash\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018, 71:1269-324. 10.1161\/HYP.0000000000000066","journal-title":"Hypertension"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032582","article-title":"Potential US population impact of the 2017 ACC\/AHA high blood pressure guideline","volume":"137","author":"Muntner P","year":"2018","unstructured":"Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, Whelton PK. Potential US population impact of the 2017 ACC\/AHA high blood pressure guideline. Circulation. 2018, 137:109-18. 10.1161\/CIRCULATIONAHA.117.032582","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group","year":"2021","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Blood Pressure Work Group: KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021, 99:S1-87. 10.1016\/j.kint.2020.11.003","journal-title":"Kidney Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright JT Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, et al.. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015, 373:2103-16. 10.1056\/NEJMoa1511939","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-Srev","article-title":"Summary of revisions: standards of care in diabetes-2023","volume":"46","author":"ElSayed NA","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al.. Summary of revisions: standards of care in diabetes-2023. Diabetes Care. 2023, 46:S5-9. 10.2337\/dc23-Srev","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey RM","year":"2018","unstructured":"Carey RM, Calhoun DA, Bakris GL, et al.. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018, 72:e53-90. 10.1161\/HYP.0000000000000084","journal-title":"Hypertension"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","article-title":"Prevalence of resistant hypertension in the United States, 2003-2008","volume":"57","author":"Persell SD","year":"2011","unstructured":"Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011, 57:1076-80. 10.1161\/HYPERTENSIONAHA.111.170308","journal-title":"Hypertension"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency cohort study","volume":"67","author":"Thomas G","year":"2016","unstructured":"Thomas G, Xie D, Chen HY, et al.. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency cohort study. Hypertension. 2016, 67:387-96. 10.1161\/HYPERTENSIONAHA.115.06487","journal-title":"Hypertension"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051455","article-title":"Rethinking resistant hypertension","volume":"11","author":"Bourque G","year":"2022","unstructured":"Bourque G, Hiremath S. Rethinking resistant hypertension. J Clin Med. 2022, 11:1455. 10.3390\/jcm11051455","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","article-title":"Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"64","author":"Muntner P","year":"2014","unstructured":"Muntner P, Davis BR, Cushman WC, et al.. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension. 2014, 64:1012-21. 10.1161\/HYPERTENSIONAHA.114.03850","journal-title":"Hypertension"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.07.038","article-title":"Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease","volume":"127","author":"Bangalore S","year":"2014","unstructured":"Bangalore S, Fayyad R, Laskey R, et al.. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med. 2014, 127:71-81.e1. 10.1016\/j.amjmed.2013.07.038","journal-title":"Am J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01448","article-title":"Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network","volume":"62","author":"Egan BM","year":"2013","unstructured":"Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013, 62:691-7. 10.1161\/HYPERTENSIONAHA.113.01448","journal-title":"Hypertension"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"71","author":"Whelton PK","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al.. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018, 71:e127-248. 10.1016\/j.jacc.2017.11.006","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313221","article-title":"Device-based neuromodulation for resistant hypertension therapy","volume":"124","author":"Lohmeier TE","year":"2019","unstructured":"Lohmeier TE, Hall JE. Device-based neuromodulation for resistant hypertension therapy. Circ Res. 2019, 124:1071-93. 10.1161\/CIRCRESAHA.118.313221","journal-title":"Circ Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1983.245.1.F1","article-title":"Renal nerves in the pathogenesis of hypertension in experimental animals and humans","volume":"245","author":"Katholi RE","year":"1983","unstructured":"Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol. 1983, 245:F1-14. 10.1152\/ajprenal.1983.245.1.F1","journal-title":"Am J Physiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60566-3","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study","volume":"373","author":"Krum H","year":"2009","unstructured":"Krum H, Schlaich M, Whitbourn R, et al.. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009, 373:1275-81. 10.1016\/S0140-6736(09)60566-3","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity HTN-2 trial): a randomised controlled trial","volume":"376","author":"Symplicity HTN-2 Investigators","year":"2010","unstructured":"Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, B\u00f6hm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010, 376:1903-9. 10.1016\/S0140-6736(10)62039-9","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt DL","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O'Neill WW, et al.. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014, 370:1393-401. 10.1056\/NEJMoa1402670","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu441","article-title":"Predictors of blood pressure response in the SYMPLICITY HTN-3 trial","volume":"36","author":"Kandzari DE","year":"2015","unstructured":"Kandzari DE, Bhatt DL, Brar S, et al.. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015, 36:219-27. 10.1093\/eurheartj\/ehu441","journal-title":"Eur Heart J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx215","article-title":"Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: state of the art and considerations for the future","volume":"38","author":"Mahfoud F","year":"2017","unstructured":"Mahfoud F, Schmieder RE, Azizi M, et al.. Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J. 2017, 38:3272-81. 10.1093\/eurheartj\/ehx215","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial","volume":"390","author":"Townsend RR","year":"2017","unstructured":"Townsend RR, Mahfoud F, Kandzari DE, et al.. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017, 390:2160-70. 10.1016\/S0140-6736(17)32281-X","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari DE","year":"2018","unstructured":"Kandzari DE, B\u00f6hm M, Mahfoud F, et al.. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018, 391:2346-55. 10.1016\/S0140-6736(18)30951-6","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi M","year":"2018","unstructured":"Azizi M, Schmieder RE, Mahfoud F, et al.. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018, 391:2335-45. 10.1016\/S0140-6736(18)31082-1","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.09.006","article-title":"A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: the RADIANCE-HTN and REQUIRE clinical study designs","volume":"195","author":"Mauri L","year":"2018","unstructured":"Mauri L, Kario K, Basile J, et al.. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: the RADIANCE-HTN and REQUIRE clinical study designs. Am Heart J. 2018, 195:115-29. 10.1016\/j.ahj.2017.09.006","journal-title":"Am Heart J"},{"key":"ref27","unstructured":"The RADIANCE II pivotal study. a study of the ReCor Medical Paradise System in Stage II hypertension (RADIANCE-II). (2023). Accessed: August 4, 2024: https:\/\/clinicaltrials.gov\/study\/NCT03614260."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2019.10.048","article-title":"Alcohol-mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension","volume":"13","author":"Mahfoud F","year":"2020","unstructured":"Mahfoud F, Renkin J, Sievert H, et al.. Alcohol-mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension. JACC Cardiovasc Interv. 2020, 13:471-84. 10.1016\/j.jcin.2019.10.048","journal-title":"JACC Cardiovasc Interv"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2015.11.041","article-title":"Transcatheter alcohol-mediated perivascular renal denervation with the peregrine system: first-in-human experience","volume":"9","author":"Fischell TA","year":"2016","unstructured":"Fischell TA, Ebner A, Gallo S, et al.. Transcatheter alcohol-mediated perivascular renal denervation with the peregrine system: first-in-human experience. JACC Cardiovasc Interv. 2016, 9:589-98. 10.1016\/j.jcin.2015.11.041","journal-title":"JACC Cardiovasc Interv"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.11.002","article-title":"Validation of a novel renal denervation system with cryoablation: a preclinical study and case series","volume":"7","author":"Ji M","year":"2022","unstructured":"Ji M, Chen H, Shen L, et al.. Validation of a novel renal denervation system with cryoablation: a preclinical study and case series. JACC Basic Transl Sci. 2022, 7:101-12. 10.1016\/j.jacbts.2021.11.002","journal-title":"JACC Basic Transl Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV10I5A110","article-title":"Renal denervation with cryoenergy as second-line option is effective in the treatment of resistant hypertension in non-responders to radiofrequency ablation","volume":"10","author":"Prochnau D","year":"2014","unstructured":"Prochnau D, Heymel S, Otto S, Figulla HR, Surber R. Renal denervation with cryoenergy as second-line option is effective in the treatment of resistant hypertension in non-responders to radiofrequency ablation. EuroIntervention. 2014, 10:640-5. 10.4244\/EIJV10I5A110","journal-title":"EuroIntervention"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.302522","article-title":"Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?","volume":"115","author":"B\u00f6hm M","year":"2014","unstructured":"B\u00f6hm M, Linz D, Ukena C, Esler M, Mahfoud F. Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?. Circ Res. 2014, 115:400-9. 10.1161\/CIRCRESAHA.115.302522","journal-title":"Circ Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV9I9A175","article-title":"What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension","volume":"9","author":"Tsioufis C","year":"2014","unstructured":"Tsioufis C, Mahfoud F, Mancia G, Redon J, Damascelli B, Zeller T, Schmieder RE. What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention. 2014, 9:1027-35. 10.4244\/EIJV9I9A175","journal-title":"EuroIntervention"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv192","article-title":"Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design","volume":"36","author":"Mahfoud F","year":"2015","unstructured":"Mahfoud F, B\u00f6hm M, Azizi M, et al.. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015, 36:2219-27. 10.1093\/eurheartj\/ehv192","journal-title":"Eur Heart J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-019-1164-2","article-title":"Renal denervation: is it ready for prime time?","volume":"21","author":"Lauder L","year":"2019","unstructured":"Lauder L, Wolf MA, Scholz SS, Hohl M, Mahfoud F, B\u00f6hm M. Renal denervation: is it ready for prime time?. Curr Cardiol Rep. 2019, 21:80. 10.1007\/s11886-019-1164-2","journal-title":"Curr Cardiol Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad D","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al.. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016, 387:957-67. 10.1016\/S0140-6736(15)01225-8","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001798","article-title":"Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis","volume":"36","author":"Kordalis A","year":"2018","unstructured":"Kordalis A, Tsiachris D, Pietri P, Tsioufis C, Stefanadis C. Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis. J Hypertens. 2018, 36:1614-21. 10.1097\/HJH.0000000000001798","journal-title":"J Hypertens"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-016-0653-6","article-title":"Non-invasive renal denervation: update on external ultrasound approaches","volume":"18","author":"Schmieder RE","year":"2016","unstructured":"Schmieder RE, Ott C, Bramlage P. Non-invasive renal denervation: update on external ultrasound approaches. Curr Hypertens Rep. 2016, 18:48. 10.1007\/s11906-016-0653-6","journal-title":"Curr Hypertens Rep"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001584","article-title":"Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV","volume":"36","author":"Schmieder RE","year":"2018","unstructured":"Schmieder RE, Ott C, Toennes SW, et al.. Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV. J Hypertens. 2018, 36:680-9. 10.1097\/HJH.0000000000001584","journal-title":"J Hypertens"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318091","article-title":"Device therapy of hypertension","volume":"128","author":"Mahfoud F","year":"2021","unstructured":"Mahfoud F, Schlaich MP, Lobo MD. Device therapy of hypertension. Circ Res. 2021, 128:1080-99. 10.1161\/CIRCRESAHA.121.318091","journal-title":"Circ Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial","volume":"58","author":"Bisognano JD","year":"2011","unstructured":"Bisognano JD, Bakris G, Nadim MK, et al.. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011, 58:765-73. 10.1016\/j.jacc.2011.06.008","journal-title":"J Am Coll Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-019-01536-5","article-title":"Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT neo system","volume":"109","author":"Wallbach M","year":"2020","unstructured":"Wallbach M, Born E, K\u00e4mpfer D, L\u00fcders S, M\u00fcller GA, Wachter R, Koziolek MJ. Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT neo system. Clin Res Cardiol. 2020, 109:513-22. 10.1007\/s00392-019-01536-5","journal-title":"Clin Res Cardiol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32337-1","article-title":"Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study","volume":"390","author":"Spiering W","year":"2017","unstructured":"Spiering W, Williams B, Van der Heyden J, et al.. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 2017, 390:2655-61. 10.1016\/S0140-6736(17)32337-1","journal-title":"Lancet"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw303","article-title":"Interventional procedures and future drug therapy for hypertension","volume":"38","author":"Lobo MD","year":"2017","unstructured":"Lobo MD, Sobotka PA, Pathak A. Interventional procedures and future drug therapy for hypertension. Eur Heart J. 2017, 38:1101-11. 10.1093\/eurheartj\/ehw303","journal-title":"Eur Heart J"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-015-0585-6","article-title":"Central iliac arteriovenous anastomosis for hypertension: targeting mechanical aspects of the circulation","volume":"17","author":"Kapil V","year":"2015","unstructured":"Kapil V, Sobotka PA, Saxena M, et al.. Central iliac arteriovenous anastomosis for hypertension: targeting mechanical aspects of the circulation. Curr Hypertens Rep. 2015, 17:585. 10.1007\/s11906-015-0585-6","journal-title":"Curr Hypertens Rep"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.25707","article-title":"The ROX coupler: creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature","volume":"85","author":"Foran JP","year":"2015","unstructured":"Foran JP, Jain AK, Casserly IP, et al.. The ROX coupler: creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature. Catheter Cardiovasc Interv. 2015, 85:880-6. 10.1002\/ccd.25707","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62053-5","article-title":"Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial","volume":"385","author":"Lobo MD","year":"2015","unstructured":"Lobo MD, Sobotka PA, Stanton A, et al.. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015, 385:1634-41. 10.1016\/S0140-6736(14)62053-5","journal-title":"Lancet"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2013.10.069","article-title":"Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension","volume":"59","author":"Faul J","year":"2014","unstructured":"Faul J, Schoors D, Brouwers S, et al.. Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. J Vasc Surg. 2014, 59:1078-83. 10.1016\/j.jvs.2013.10.069","journal-title":"J Vasc Surg"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.00064","article-title":"The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases","volume":"61","author":"Paton JF","year":"2013","unstructured":"Paton JF, Sobotka PA, Fudim M, et al.. The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension. 2013, 61:5-13. 10.1161\/HYPERTENSIONAHA.111.00064","journal-title":"Hypertension"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2016.06.004","article-title":"Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial","volume":"1","author":"Narkiewicz K","year":"2016","unstructured":"Narkiewicz K, Ratcliffe LE, Hart EC, et al.. Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial. JACC Basic Transl Sci. 2016, 1:313-24. 10.1016\/j.jacbts.2016.06.004","journal-title":"JACC Basic Transl Sci"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy565.1416","article-title":"1416Transvenous carotid body ablation for resistant hypertension: main results of a multicentre safety and proof-of-principle cohort study","volume":"39","author":"Schlaich M","year":"2018","unstructured":"Schlaich M, Schultz C, Shetty S, et al.. 1416Transvenous carotid body ablation for resistant hypertension: main results of a multicentre safety and proof-of-principle cohort study. Eur Heart J. 2018, 39:ehy565.1416. 10.1093\/eurheartj\/ehy565.1416","journal-title":"Eur Heart J"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511643","article-title":"A leadless intracardiac transcatheter pacing system","volume":"374","author":"Reynolds D","year":"2016","unstructured":"Reynolds D, Duray GZ, Omar R, et al.. A leadless intracardiac transcatheter pacing system. N Engl J Med. 2016, 374:533-41. 10.1056\/NEJMoa1511643","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006974","article-title":"Pacemaker-mediated programmable hypertension control therapy","volume":"6","author":"Neuzil P","year":"2017","unstructured":"Neuzil P, Merkely B, Erglis A, et al.. Pacemaker-mediated programmable hypertension control therapy. J Am Heart Assoc. 2017, 6:e006974. 10.1161\/JAHA.117.006974","journal-title":"J Am Heart Assoc"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020492","article-title":"Pacemaker-based cardiac neuromodulation therapy in patients with hypertension: a pilot study","volume":"10","author":"Kalarus Z","year":"2021","unstructured":"Kalarus Z, Merkely B, Neu\u017eil P, et al.. Pacemaker-based cardiac neuromodulation therapy in patients with hypertension: a pilot study. J Am Heart Assoc. 2021, 10:e020492. 10.1161\/JAHA.120.020492","journal-title":"J Am Heart Assoc"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022622","article-title":"Pacemaker-based cardiac neuromodulation therapy for the treatment of hypertension: the new kid on the block","volume":"10","author":"Lauder L","year":"2021","unstructured":"Lauder L, Mahfoud F. Pacemaker-based cardiac neuromodulation therapy for the treatment of hypertension: the new kid on the block. J Am Heart Assoc. 2021, 10:e022622. 10.1161\/JAHA.121.022622","journal-title":"J Am Heart Assoc"},{"key":"ref56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jash.2016.03.022","article-title":"Median nerve modulation: a novel approach to resistant hypertension","volume":"10","author":"Webster M","year":"2016","unstructured":"Webster M, Valle M, Blake J, et al.. Median nerve modulation: a novel approach to resistant hypertension. J Am Soc Hypertens. 2016, 10:e8-9.","journal-title":"J Am Soc Hypertens"},{"key":"ref57","unstructured":"Valencia technologies announces FDA approval of eCoin\u00ae therapy to treat urinary urge incontinence. (2022). Accessed. August 4, 2024: https:\/\/valenciatechnologies.com\/valencia-technologies-announces-fda-approval-of-ecoin-therapy-to-treat-urinary-urge-...."},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2006.04.015","article-title":"Deep brain stimulation: a new treatment for hypertension?","volume":"14","author":"Green AL","year":"2007","unstructured":"Green AL, Wang S, Bittar RG, et al.. Deep brain stimulation: a new treatment for hypertension?. J Clin Neurosci. 2007, 14:592-5. 10.1016\/j.jocn.2006.04.015","journal-title":"J Clin Neurosci"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00093","article-title":"Potential deep brain stimulation targets for the management of refractory hypertension","volume":"13","author":"Ems R","year":"2019","unstructured":"Ems R, Garg A, Ostergard TA, Miller JP. Potential deep brain stimulation targets for the management of refractory hypertension. Front Neurosci. 2019, 13:93. 10.3389\/fnins.2019.00093","journal-title":"Front Neurosci"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0128-2","article-title":"Deep brain stimulation: current challenges and future directions","volume":"15","author":"Lozano AM","year":"2019","unstructured":"Lozano AM, Lipsman N, Bergman H, et al.. Deep brain stimulation: current challenges and future directions. Nat Rev Neurol. 2019, 15:148-60. 10.1038\/s41582-018-0128-2","journal-title":"Nat Rev Neurol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2023.51","article-title":"The Global burden of resistant hypertension and potential treatment options","volume":"19","author":"Buso G","year":"2024","unstructured":"Buso G, Agabiti-Rosei C, Lemoli M, Corvini F, Muiesan ML. The Global burden of resistant hypertension and potential treatment options. Eur Cardiol. 2024, 19:e07. 10.15420\/ecr.2023.51","journal-title":"Eur Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/245403-hypertension-and-device-based-therapies-for-resistant-hypertension-an-up-to-date-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T17:27:02Z","timestamp":1722965222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/245403-hypertension-and-device-based-therapies-for-resistant-hypertension-an-up-to-date-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":61,"URL":"https:\/\/doi.org\/10.7759\/cureus.66304","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,6]]}}}